首页> 外文期刊>Polymers for advanced technologies >Intravenous infusion of Hb-vesicles (artificial oxygen carriers) after repetitive blood exchange with a series of plasma expanders (water-soluble biopolymers) in a rat modely
【24h】

Intravenous infusion of Hb-vesicles (artificial oxygen carriers) after repetitive blood exchange with a series of plasma expanders (water-soluble biopolymers) in a rat modely

机译:在大鼠中以一系列血浆扩张剂(水溶性生物聚合物)反复换血后,静脉注射Hb囊泡(人工氧气载体)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Hemoglobin-vesicles (HbV) are artificial oxygen carriers developed for use as a transfusion alternative. The extremely high concentration of the HbV suspension (solutes, ca. 16 g/dl; volume fraction, ca. 40 vol.%) provides a sufficient oxygen carrying capacity to maintain oxygen metabolism. A suspension of HbV has no colloid osmotic pressure (COP). Consequently, a combination of a plasma expander is necessary for a massive dose of HbV. Clinically available plasma expanders include hydroxyethyl starch (HES), modified gelatin (MFG), or recombinant human serum albumin (rHSA). Our previous studies confirmed that these water-soluble biopolymers interact with HbV to induce flocculation of HbV reversibly by depletion interaction, especially with MFG and high molecular weight HES. It remains unknown whether such flocculate formation in blood might affect animal's hemodynamics. Using a rat model, we tested infusion of a series of plasma expander to maintain the blood volume (level of blood exchange led to 60%) at repeated hemorrhages and the subsequent infusion of HbV (20 ml/kg, 36% of blood volume). All rats survived for 4 hr after the infusion of HbV; hemodynamic and respiratory functions were preserved, indicating that the flocculation does not induce capillary embolism. Blood exchange with rHSA and subsequent infusion of HbV showed more stable systemic parameters because of the longer retention of rHSA in blood than other plasma substitutes, indicating that rHSA is suitable for combination with HbV in this experimental model.
机译:血红蛋白囊泡(HbV)是人工氧气载体,被开发用作输血替代品。 HbV悬浮液的极高浓度(溶质,约16 g / dl;体积分数,约40 vol。%)提供了足够的载氧能力,以维持氧的代谢。 HbV的悬浮液没有胶体渗透压(COP)。因此,对于大剂量的HbV,必须使用血浆膨胀剂的组合。临床上可用的血浆膨胀剂包括羟乙基淀粉(HES),改性明胶(MFG)或重组人血清白蛋白(rHSA)。我们以前的研究证实,这些水溶性生物聚合物与HbV相互作用,通过耗竭相互作用可逆地诱导HbV絮凝,特别是与MFG和高分子量HES相互作用。血液中这种絮凝物的形成是否会影响动物的血液动力学尚不清楚。使用大鼠模型,我们测试了输注一系列血浆扩张剂以在反复出血时维持血容量(血液交换水平导致60%)以及随后输注HbV(20 ml / kg,占血容量的36%) 。注射HbV后,所有大鼠均存活4小时。血液动力学和呼吸功能得以保留,表明絮凝不会引起毛细血管栓塞。与其他血浆代用品相比,由于rHSA在血液中的保留时间更长,因此与rHSA进行血液交换和随后的HbV输注显示出更稳定的系统参数,这表明rHSA适合在该实验模型中与HbV联合使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号